Product Image
Please see full prescribing and safety information, including boxed warning, for CYTARABINE 100 mg per 5 mL and 2 g per 20 mL single-dose vials.

Available in:

  • 100 mg per 5 mL single-dose vials
  • 2 g per 20 mL single-dose vials


  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex


Therapeutic Category: Antineoplastic Agent

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
Description Strength Fill
Concentration Container
Closure Unit
of Sale
229-05 Glass Vial 100 mg 5 mL 20 mg per mL 5 mL 13 mm 5
223-20 Glass Vial 2 g 20 mL 100 mg per mL 20 mL 20 mm 1


Only physicians experienced in cancer chemotherapy should use Cytarabine Injection.

For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of Cytarabine Injection is bone marrow suppression with leukopenia, thrombocytopenia and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction.

The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with Cytarabine Injection. Before making this judgement or beginning treatment, the physician should be familiar with the following text.